Skip to main content
OSTI.GOVU.S. Department of Energy Office of Scientific and Technical Information
U.S. Department of Energy
Office of Scientific and Technical Information
 

Imatinib can act as an Allosteric Activator of Abl Kinase

Journal Article · · J. Mol. Biol.
; ; ; ;

Research Organization:
Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
Sponsoring Organization:
DOE - Office Of Science; National Institutes of Health (NIH)
OSTI ID:
1839714
Journal Information:
J. Mol. Biol., Vol. 434, Issue (2)
Country of Publication:
United States
Language:
ENGLISH

References (52)

Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom? October 2016
Response and Resistance to BCR-ABL1-Targeted Therapies April 2020
Conformational states dynamically populated by a kinase determine its function October 2020
The development of imatinib as a therapeutic agent for chronic myeloid leukemia April 2005
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification June 2001
Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the fr: BCR-ABL KD Mutations in Ph+ ALL December 2013
Resistance in chronic myeloid leukemia: definitions and novel therapeutic agents January 2018
AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance November 2009
Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation February 2015
Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion September 2016
Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study March 2014
Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia November 2013
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants August 2017
Allosteric inhibitors of Bcr-abl–dependent cell proliferation January 2006
Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors January 2010
The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1 March 2017
Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase March 2003
Atomic view of the energy landscape in the allosteric regulation of Abl kinase September 2017
Binding or Bending: Distinction of Allosteric Abl Kinase Agonists from Antagonists by an NMR-Based Conformational Assay May 2010
Discovery and Characterization of a Cell-Permeable, Small-Molecule c-Abl Kinase Activator that Binds to the Myristoyl Binding Site February 2011
Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants October 2019
Solution Conformations and Dynamics of ABL Kinase-Inhibitor Complexes Determined by NMR Substantiate the Different Binding Modes of Imatinib/Nilotinib and Dasatinib April 2008
Energetic dissection of Gleevec's selectivity toward human tyrosine kinases September 2014
A conserved protonation-dependent switch controls drug binding in the Abl kinase December 2008
Crystal Structures of ABL-Related Gene (ABL2) in Complex with Imatinib, Tozasertib (VX-680), and a Type I Inhibitor of the Triazole Carbothioamide Class March 2011
Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis October 2011
c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF September 1999
Mechanisms of drug resistance in kinases January 2011
Present and future of molecular monitoring in chronic myeloid leukaemia March 2016
Pharmacokinetics and Pharmacodynamics of Imatinib in a Phase I Trial With Chronic Myeloid Leukemia Patients March 2004
BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia September 2014
In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants June 2005
Kinase-Independent Mechanisms of Resistance of Leukemia Stem Cells to Tyrosine Kinase Inhibitors March 2014
NMR reveals the allosteric opening and closing of Abelson tyrosine kinase by ATP-site and myristoyl pocket inhibitors November 2013
ATP Site Ligands Determine the Assembly State of the Abelson Kinase Regulatory Core via the Activation Loop Conformation January 2018
Cyclophilin A promotes cell migration via the Abl-Crk signaling pathway December 2015
Structural basis for regulation of the Crk signaling protein by a proline switch December 2010
Exploiting E. coli auxotrophs for leucine, valine, and threonine specific methyl labeling of large proteins for NMR applications June 2016
Structural basis for client recognition and activity of Hsp40 chaperones September 2019
NMRPipe: A multidimensional spectral processing system based on UNIX pipes November 1995
NMRFAM-SPARKY: enhanced software for biomolecular NMR spectroscopy December 2014
15N and 13C- SOFAST-HMQC editing enhances 3D-NOESY sensitivity in highly deuterated, selectively [1H,13C]-labeled proteins November 2016
Automatic methyl assignment in large proteins by the MAGIC algorithm November 2017
Integration, scaling, space-group assignment and post-refinement January 2010
How good are my data and what is the resolution? June 2013
Phaser crystallographic software July 2007
Features and development of Coot March 2010
Refinement of Macromolecular Structures by the Maximum-Likelihood Method May 1997
Studying “Invisible” Excited Protein States in Slow Exchange with a Major State Conformation April 2012
13CHD2–CEST NMR spectroscopy provides an avenue for studies of conformational exchange in high molecular weight proteins August 2015
Probing Side-Chain Dynamics in the Proteasome by Relaxation Violated Coherence Transfer NMR Spectroscopy February 2007
An Optimized Relaxation-Based Coherence Transfer NMR Experiment for the Measurement of Side-Chain Order in Methyl-Protonated, Highly Deuterated Proteins December 2011

Similar Records

The Structure of Dasatinib (BNS-354825) Bound to Activated ABL Kinase Domain Elucidates its Inhibitory Activity Against Imatinib-Resistant ABL Mutants
Journal Article · 2006 · Cancer Research · OSTI ID:930208
+6 more
Crystal Structures of the Kinase Domain of c-Abl in Complex withthe Small Molecule Inhibitors PD173955 and Imatinib (STI-571)
Journal Article · 2002 · Cancer Research · OSTI ID:881422
+5 more
Analysis of Imatinib and Sorafenib Binding to p38 Compared with c-Abl and b-Raf Provides Structural Insights for Understanding the Selectivity of Inhibitors Targeting the DFG-Out Form of Protein Kinases
Journal Article · 2010 · Biochemistry · OSTI ID:1019870
+3 more

Related Subjects